Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350998 | 0.86 | GPR119 (0.39) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL27496528 | 0.85 | GPR119 (0.37) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL8820197 | 0.84 | GPR119 (0.46) | GPR119CYP3A4FPR2USP30NR3C1 | |
| SCHEMBL8818888 | 0.82 | GPR119 (0.44) | GPR119FPR2USP30 | |
| SCHEMBL31583380 | 0.82 | GPR119 (0.44) | GPR119FPR2USP30NR3C1 | |
| SCHEMBL7350588 | 0.82 | GPR119 (0.49) | GPR119CYP3A4CYP2C9FPR2USP30 | |
| SCHEMBL15656816 | 0.82 | GPR119 (0.44) | GPR119CYP3A4FPR2USP30NR3C1 | |
| SCHEMBL27497857 | 0.81 | GPR119 (0.35) | GPR119 | |
| SCHEMBL27498178 | 0.79 | NSD3 (0.36) | CYP3A4 | |
| SCHEMBL31565579 | 0.79 | GPR119 (0.48) | GPR119USP30NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912555-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997049699-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |